– ATNM-400 is a novel, non-PSMA targeting, first-in-class Actinium-225 radiotherapy for prostate cancer with initial preclinical results to be presented at the AACR Annual Meeting – Actinium is establishing radiopharmaceutical manufacturing infrastructure in 2025 to support expanding…

The Company continues to work diligently to file its 2024 SEC reports ST. LOUIS , March 27, 2025 /PRNewswire/ — Latch, Inc. (“Latch” or the “Company”), soon to be DOOR, today announced that on March 26, 2025, the Company filed its Annual Report on Form 10-K for the year ended December…

HILLERØD, Denmark, March 27, 2025 /PRNewswire/ — Ellab, the leading provider of validation, monitoring, and calibration services and solutions, announces that it has appointed Gergely Sved as its new Chief Executive Officer (CEO), following the departure of Ludvig Enlund. Mr Sved will…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.